Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Research and development expenses	$ 469	$ 468	$ 1,570	$ 1,357
Marketing expenses	297	24	631	205
General and administrative expenses	431	384	1,448	1,138
Total operating loss	1,197	876	3,649	2,700
Financial income, net	(18)	(20)	(11)	(56)
Loss for the period	$ 1,179	$ 856	$ 3,638	$ 2,644
Basic loss per common stock	$ (0.02)	$ (0.01)	$ (0.05)	$ (0.04)
Dilutive loss per common stock	$ (0.02)	$ (0.01)	$ (0.05)	$ (0.04)
Weighted average number of ordinary shares basic	68,836,598	68,720,970	69,233,573	67,186,877
Weighted average number of ordinary shares diluted	68,836,598	68,720,970	69,233,573	67,186,877